Literature DB >> 10761559

Mixed cryoglobulinemia in hepatitis C patients. GERMIVIC.

P Cacoub1, P Hausfater, L Musset, J C Piette.   

Abstract

Cryoglobulins are immunoglobulins that persist in the serum, precipitate with cold temperature and resolubilize when rewarmed. Types II and III are mixed cryoglobulins (MC), composed of different immunoglobulins, with a monoclonal component in type II and only polyclonal immunoglobulins in type III. Mixed cryoglobulins are associated with connective-tissue disease, malignant hematological disorder (type B lymphoproliferation) or obvious infectious process. Mixed cryoglobulinemia syndrome is characterized by the clinical triad of purpura, arthralgia and asthenia associated with type II or type III MC. The disorder is the consequence of an immune-complex-type vasculitis as supported by clinical features, analysis of the cryoglobulins, the usually depressed level of complement during the active phase of the disease, and the deposition of immunoglobulins and complement in the lesions. Such cryoglobulinemia vasculitis may involve numerous organs, particularly the peripheral nervous system and the kidneys. MC is frequently associated with clinical and biological evidence of liver disease. There has been some controversy about which comes first, MC or chronic liver disease, but it seems fairly clear that MC is often a manifestation of underlying chronic active or persistent hepatitis. In MC patients, the hepatotropic antigen(s) capable of triggering production of antibodies which can later form immune complexes has been sought for many years. In the last ten years, numerous studies have demonstrated that infection with hepatitis C virus is involved in the pathogenesis of most mixed cryoglobulinemia. This review analyzes the main published data on hepatitis C virus-mixed cryoglobulinemia, the role of liver alterations, the predictive factors associated with MC production in HCV patients and its symptomatic nature or not, and the different types of vasculitis associated with HCV chronic infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761559

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  5 in total

1.  Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.

Authors:  Edgar D Charles; Claudia Brunetti; Svetlana Marukian; Kimberly D Ritola; Andrew H Talal; Kristen Marks; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2011-03-18       Impact factor: 22.113

2.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population.

Authors:  L Santoro; F Manganelli; C Briani; F Giannini; L Benedetti; E Vitelli; A Mazzeo; E Beghi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02-07       Impact factor: 10.154

4.  Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases.

Authors:  Cesare Mazzaro; Luigino Dal Maso; Endri Mauro; Valter Gattei; Michela Ghersetti; Pietro Bulian; Giulia Moratelli; Gabriele Grassi; Francesca Zorat; Gabriele Pozzato
Journal:  Diseases       Date:  2018-05-03

Review 5.  Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC).

Authors:  Cesare Mazzaro; Luigino Dal Maso; Laura Gragnani; Marcella Visentini; Francesco Saccardo; Davide Filippini; Pietro Andreone; Anna Linda Zignego; Valter Gattei; Giuseppe Monti; Massimo Galli; Luca Quartuccio
Journal:  Viruses       Date:  2021-05-30       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.